DOCSLIB.ORG

Linking Molecular Scale Insights to Population Impacts Paul A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

UNIT 1. UNIT 1 CONTEXTUAL FRAMEWORK FOR MOLECULAR EPIDEMIOLOGY CHAPTER 1 CHAPTER CHAPTER 1. Molecular epidemiology: Linking molecular scale insights to population impacts Paul A. Schulte, Nathaniel Rothman, Pierre Hainaut, Martyn T. Smith, Paolo Boffetta, and Frederica P. Perera Summary In a broad sense, molecular trials. It can then contribute to of using these and other tools to epidemiology is the axis that unites the translation of biomedical prevent, control, and treat chronic insights at the molecular level research into practical public and infectious diseases stimulates and understanding of disease at health and clinical applications the imagination and creativity of the population level. It is also a by addressing the medical and medical and health scientists and partnership between epidemiologists population implications of molecular practitioners. The challenge is and laboratory scientists in which phenomena in terms of reducing to effectively apply these tools, investigations are conducted using risk of disease. This chapter and knowledge from genetics, the principles of both disciplines. A summarizes the contributions and exposure assessment, population key trait of molecular epidemiology research endeavours of molecular health and medicine, to health is to evaluate and establish the epidemiology and how they link with problems that afflict 21st century relationship between a biomarker public health initiatives and clinical people. The means of meeting and important exogenous practice. that challenge is the widespread and endogenous exposures, conduct of molecular epidemiologic susceptibility, or disease, providing Introduction research. Driven by discoveries understanding that can be used in of basic biological phenomena future research and public health This is a unique and exciting at the molecular and genetic and clinical practice. When potential period in the health sciences. levels, molecular epidemiology solutions or interventions are For the first time, it is possible to is able to translate discovery of identified, molecular epidemiology look at both nature and nurture essential scientific knowledge into is also useful in developing and with sophisticated and molecular- determination and quantification conducting clinical and intervention level tools (1–12). The promise of hazards and risks, and then to Unit 1 • Chapter 1. Molecular epidemiology: Linking molecular scale 1 investigate useful approaches for comprehensive framework for the which brings together molecular- prevention, control, and treatment of use of biomarkers of internal dose, level thinking and population-level disease and dysfunction (9,12–15). biologically effective dose, early understanding. These insights can To fully appreciate the potential biologic effect and susceptibility be useful in characterizing a health contributions of molecular within a molecular epidemiological problem, conducting mechanistic epidemiology, it is important framework (2). In 1987, the National research (at the molecular and to understand how it fits into Research Council (NRC) adopted population levels), understanding the context of epidemiology this basic conceptual framework the solutions, and contributing and public health. Molecular for molecular epidemiology and to the clinical and public health epidemiology is a partnership subsequently published a series practice. These four functions and between epidemiologists and of reports on biological markers the research that supports them are laboratory scientists that conducts (20–22). In the 1980s through the illustrated in Figure 1.1. investigations using the principles mid-1990s, a series of important of both laboratory and population papers and books were published Characterizing research (1,2,16). This is a message describing the evolution and a public health problem that merits restatement as powerful progress of molecular epidemiology genetic and analytic technologies (1,17,23–36). More recently, the Surveillance, the sentinel activity of become available to epidemiologists. changing face of epidemiology in public health and clinical practice, is Historically, molecular epidemiology the genomics and epigenetic eras the ongoing collection, analysis and was derived from those disciplines has been described (9,12,36–39). interpretation of data on rates and that made contributions to relating In the past, molecular trends of disease, injury, death and biological measurements to health epidemiology was sometimes hazards. Molecular epidemiology and disease (1,2). These include viewed as one of epidemiology’s plays an important role in surveillance bacteriology, immunology and many subspecialties. Some by identifying the frequency of infectious disease epidemiology; subspecialties focus on the disease biological markers of exposure, pathology and clinical chemistry; type (e.g. chronic, infectious, disease or susceptibility in various carcinogenesis and oncology; reproductive or cardiovascular), population groups and in monitoring occupational medicine and some on the origin of the hazard trends of biomarkers over time. toxicology; cardiovascular disease (e.g. occupational, environmental Examples are population monitoring epidemiology; genetics, molecular or nutritional), and still others of blood lead concentrations, biology, and genetic epidemiology; focus on the approach to the neonatal screening for genetic and traditional epidemiology and disease (e.g. clinical, serological or disease, and molecular typing of biostatistics. The term “molecular analytical). Viewed in this context, viruses in a geographical area. epidemiology” was first used in molecular epidemiology may best The validation of those biomarkers the infectious disease literature by fit into the category of subspecialty and the analysis of the data involve Kilbourne to describe the “molecular defined by the approach that is molecular epidemiologic skills and determinants of epidemiologic applicable to all of these areas. knowledge. Increasingly, biological events” (17). In 1977, Higginson used Molecular epidemiology is the use specimen banks are being used as the term in the context of pathology of all types of biological markers public health surveillance systems in a paper entitled “The role of in the investigation of the cause, (40) and can play an important role the pathologist in environmental distribution, prevention and in etiologic research (41). medicine and public health” (18). treatment of disease, in which Lower’s landmark 1979 publication biological markers are used to Mechanistic research introduced genetic effect modifiers represent exposures, intervening and brought attention to the factors, susceptibility, intermediate Establishing the relationship importance of external exposure, pathological events, preclinical and between a biomarker and exposure, individual susceptibility and biologic clinical disease, or prognosis. disease or susceptibility is the markers in terms of phenotype (19). More broadly, molecular hallmark of molecular epidemiology, In a seminal paper in 1982, Perera epidemiology can be viewed as a hub and leads to developing the and Weinstein coined the term that links various aspects of health knowledge that will eventually be “molecular cancer epidemiology” research. Even the term molecular used in further research and in and first proposed a formal and epidemiology is a linking term clinical and public health practice. 2 Figure 1.1. Molecular epidemiology can serve as a hub for other components of Clinical UNIT 1 health research and practice. Adapted from (74). and public health practice CHAPTER 1 CHAPTER Translation of biomedical research to useful clinical and public health applications is clearly a major challenge (15,42–44). Molecular epidemiologists can accept that challenge and contribute to the translation of knowledge from research endeavours. This entails a more expansive view of molecular epidemiology beyond a tool in etiologic research to a discipline Figure not available that addresses the medical and population ramifications of molecular phenomena in terms of reducing risk of disease (45). Translation is a multifaceted process that has been described as involving four phases: 1) discovery to candidate health application; 2) health application to evidence-based practice guidelines; 3) practice guidelines to health practice; and 4) practice to population health impact (44). At times, molecular epidemiology has been portrayed as a reductionist approach that merely identifies molecular To achieve this progression, there assessment in trials, there is a risk factors and indicators in is a need for parallel laboratory and need for research on the translation individuals. However, molecular population research to understand of findings to clinical and public epidemiology is first and foremost the mechanisms through which health practitioners. This involves a means to gain sufficient environmental exposures interact identifying the potential uses of the biological understanding at the with host susceptibility factors to findings, the plan for communicating molecular and biochemical level of increase the risk of disease. The key and disseminating this information, the process of disease causation mechanisms can then be blocked and ways to measure the impact to protect public health. From its by interventions, such as exposure of their use. Epidemiologists have outset, molecular epidemiology reduction, behaviour modification, a long history of providing the has had the vision that biological chemoprevention
Recommended publications
  • Communicable Disease Chart

    Communicable Disease Chart

    COMMON INFECTIOUS ILLNESSES From birth to age 18 Disease, illness or organism Incubation period How is it spread? When is a child most contagious? When can a child return to the Report to county How to prevent spreading infection (management of conditions)*** (How long after childcare center or school? health department* contact does illness develop?) To prevent the spread of organisms associated with common infections, practice frequent hand hygiene, cover mouth and nose when coughing and sneezing, and stay up to date with immunizations. Bronchiolitis, bronchitis, Variable Contact with droplets from nose, eyes or Variable, often from the day before No restriction unless child has fever, NO common cold, croup, mouth of infected person; some viruses can symptoms begin to 5 days after onset or is too uncomfortable, fatigued ear infection, pneumonia, live on surfaces (toys, tissues, doorknobs) or ill to participate in activities sinus infection and most for several hours (center unable to accommodate sore throats (respiratory diseases child’s increased need for comfort caused by many different viruses and rest) and occasionally bacteria) Cold sore 2 days to 2 weeks Direct contact with infected lesions or oral While lesions are present When active lesions are no longer NO Avoid kissing and sharing drinks or utensils. (Herpes simplex virus) secretions (drooling, kissing, thumb sucking) present in children who do not have control of oral secretions (drooling); no exclusions for other children Conjunctivitis Variable, usually 24 to Highly contagious;
  • 797 Circulating Tumor DNA and Circulating Tumor Cells for Cancer

    797 Circulating Tumor DNA and Circulating Tumor Cells for Cancer

    Medical Policy Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) Table of Contents • Policy: Commercial • Coding Information • Information Pertaining to All Policies • Policy: Medicare • Description • References • Authorization Information • Policy History • Endnotes Policy Number: 797 BCBSA Reference Number: 2.04.141 Related Policies Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer, #336 Policy1 Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Plasma-based comprehensive somatic genomic profiling testing (CGP) using Guardant360® for patients with Stage IIIB/IV non-small cell lung cancer (NSCLC) is considered MEDICALLY NECESSARY when the following criteria have been met: Diagnosis: • When tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP or invasive biopsy is medically contraindicated), AND • When prior results for ALL of the following tests are not available: o EGFR single nucleotide variants (SNVs) and insertions and deletions (indels) o ALK and ROS1 rearrangements o PDL1 expression. Progression: • Patients progressing on or after chemotherapy or immunotherapy who have never been tested for EGFR SNVs and indels, and ALK and ROS1 rearrangements, and for whom tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP), OR • For patients progressing on EGFR tyrosine kinase inhibitors (TKIs). If no genetic alteration is detected by Guardant360®, or if circulating tumor DNA (ctDNA) is insufficient/not detected, tissue-based genotyping should be considered. Other plasma-based CGP tests are considered INVESTIGATIONAL. CGP and the use of circulating tumor DNA is considered INVESTIGATIONAL for all other indications. 1 The use of circulating tumor cells is considered INVESTIGATIONAL for all indications.
  • Study Guide Medical Terminology by Thea Liza Batan About the Author

    Study Guide Medical Terminology by Thea Liza Batan About the Author

    Study Guide Medical Terminology By Thea Liza Batan About the Author Thea Liza Batan earned a Master of Science in Nursing Administration in 2007 from Xavier University in Cincinnati, Ohio. She has worked as a staff nurse, nurse instructor, and level department head. She currently works as a simulation coordinator and a free- lance writer specializing in nursing and healthcare. All terms mentioned in this text that are known to be trademarks or service marks have been appropriately capitalized. Use of a term in this text shouldn’t be regarded as affecting the validity of any trademark or service mark. Copyright © 2017 by Penn Foster, Inc. All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the copyright owner. Requests for permission to make copies of any part of the work should be mailed to Copyright Permissions, Penn Foster, 925 Oak Street, Scranton, Pennsylvania 18515. Printed in the United States of America CONTENTS INSTRUCTIONS 1 READING ASSIGNMENTS 3 LESSON 1: THE FUNDAMENTALS OF MEDICAL TERMINOLOGY 5 LESSON 2: DIAGNOSIS, INTERVENTION, AND HUMAN BODY TERMS 28 LESSON 3: MUSCULOSKELETAL, CIRCULATORY, AND RESPIRATORY SYSTEM TERMS 44 LESSON 4: DIGESTIVE, URINARY, AND REPRODUCTIVE SYSTEM TERMS 69 LESSON 5: INTEGUMENTARY, NERVOUS, AND ENDOCRINE S YSTEM TERMS 96 SELF-CHECK ANSWERS 134 © PENN FOSTER, INC. 2017 MEDICAL TERMINOLOGY PAGE III Contents INSTRUCTIONS INTRODUCTION Welcome to your course on medical terminology. You’re taking this course because you’re most likely interested in pursuing a health and science career, which entails ­proficiency­in­communicating­with­healthcare­professionals­such­as­physicians,­nurses,­ or dentists.
  • Medical Microbiology and Infectious Diseases 22% Specialists in 2017 = 11%3

    Medical Microbiology and Infectious Diseases 22% Specialists in 2017 = 11%3

    Medical Microbiology & Infectious Diseases Profile Updated December 2019 1 Table of Contents Slide . General Information 3-5 . Total number & number/100,000 population by province, 2019 6 . Number/100,000 population, 1995-2019 7 . Number by gender & year, 1995-2019 8 . Percentage by gender & age, 2019 9 . Number by gender & age, 2019 10 . Percentage by main work setting, 2019 11 . Percentage by practice organization, 2017 12 . Hours worked per week (excluding on-call), 2019 13 . On-call duty hours per month, 2019 14 . Percentage by remuneration method 15 . Professional & work-life balance satisfaction, 2019 16 . Number of retirees during the three year period of 2016-2018 17 . Employment situation, 2017 18 . Links to additional resources 19 2 General information Microbiology and infectious diseases focuses on the diagnosis and treatment of infectious diseases; thus, it is concerned with human illness due to micro-organisms. Since such disease can affect any and all organs and systems, this specialist must be prepared to deal with any region of the body. The specialty of Medical Microbiology and Infectious Disease consists primarily of four major spheres of activity: 1. the provision of clinical consultations on the investigation, diagnosis and treatment of patients suffering from infectious diseases; 2. the establishment and direction of infection control programs across the continuum of care; 3. public health and communicable disease prevention and epidemiology; 4. the scientific and administrative direction of a diagnostic microbiology laboratory. Source: Pathway evaluation program 3 General information Once you’ve completed medical school, it takes an additional 5 years of Royal College-approved residency training to become certified in medical microbiology and infectious disease.
  • Diagnostic Tests Diagnostic Tests Attempt to Classify Whether Somebody Has a Disease Or Not Before Symptoms Are Present

    Diagnostic Tests Diagnostic Tests Attempt to Classify Whether Somebody Has a Disease Or Not Before Symptoms Are Present

    community project encouraging academics to share statistics support resources All stcp resources are released under a Creative Commons licence stcp-rothwell-diagnostictests Diagnostic Tests Diagnostic tests attempt to classify whether somebody has a disease or not before symptoms are present. We are interested in detecting the disease early, while it is still curable. However, there is a need to establish how good a diagnostic test is in detecting disease. In this situation a 2x2 table similar to the below would be produced to test how effective a diagnostic test is at predicting the outcome of interest. A number of different measures can be calculated from this information. True Diagnosis Disease +ve Disease -ve Total Test Results +ve a b a+b -ve c d c+d a+c b+d N = This is the proportion of diseased individuals that are correctly Sensitivity: ( ) identified by the test as having the disease. (+ | ) + = This is the proportion of non-diseased individuals that Specificity: ( ) are correctly identified by the test as not having the disease. ( | ) + = This is the proportion − of individuals with Positive Predictive Value**: ( ) positive test results that are correctly diagnosed and actually have the disease. ( | + ) + = This is the proportion of individuals with Negative Predictive Value**: ( ) negative test results that are correctly diagnosed and do not have the disease. ( | + ) − © Joanne Rothwell Reviewer: Chris Knox University of Sheffield University of Sheffield Medical Statistics – diagnostic tests Positive Likelihood Ratio: = This gives a ratio of the test being positive + for patients with disease compared with those without disease. Aim to be much greater − than 1 for a good test.
  • Burden of Disease: What Is It and Why Is It Important for Safer Food?

    Burden of Disease: What Is It and Why Is It Important for Safer Food?

    Burden of disease: what is it and why is it important for safer food? What is ‘burden of disease’? Burden of disease is concept that was developed in the 1990s by the Harvard School of Public Health, the World Bank and the World Health Organization (WHO) to describe death and loss of health due to diseases, injuries and risk factors for all regions of the world.1 The burden of a particular disease or condition is estimated by adding together: • the number of years of life a person loses as a consequence of dying early because of the disease (called YLL, or Years of Life Lost); and • the number of years of life a person lives with disability caused by the disease (called YLD, or Years of Life lived with Disability). Adding together the Years of Life Lost and Years of Life lived with Disability gives a single-figure estimate of disease burden, called the Disability Adjusted Life Year (or DALY). One DALY represents the loss of one year of life lived in full health (see text box for more explanation and examples). Looking at burden of disease using DALYs can reveal surprises about a population’s health. For example, the Global Burden of Disease 2004 Update suggests that neuropsychiatric conditions are the most important causes of disability in all regions of the world, accounting for around 33% of all years lived with disability among adults aged 15 years and over, but only 2.2% of deaths.2 Therefore while psychiatric disorders are not traditionally regarded as having a major impact on the health of populations, this picture is completely altered when the burden of disease is estimated using DALYs.
  • Genomic Epidemiology and Recent Update on Nucleic Acid–Based Diagnostics for COVID-19

    Genomic Epidemiology and Recent Update on Nucleic Acid–Based Diagnostics for COVID-19

    Current Tropical Medicine Reports https://doi.org/10.1007/s40475-020-00212-3 COVID-19 IN THE TROPICS: IMPACT AND SOLUTIONS (AJ RODRIGUEZ-MORALES, SECTION EDITOR)) Genomic Epidemiology and Recent Update on Nucleic Acid–Based Diagnostics for COVID-19 Ali A. Rabaan1 & Shamsah H. Al-Ahmed2 & Ranjit Sah3 & Jaffar A. Al-Tawfiq4,5,6 & Shafiul Haque7 & Harapan Harapan8,9,10 & Kovy Arteaga-Livias11,12 & D. Katterine Bonilla Aldana13,14 & Pawan Kumar 15 & Kuldeep Dhama16 & Alfonso J. Rodriguez-Morales12,13,14,17 Accepted: 10 September 2020 # Springer Nature Switzerland AG 2020 Abstract Purpose of the Review The SARS-CoV-2 genome has been sequenced and the data is made available in the public domain. Molecular epidemiological investigators have utilized this information to elucidate the origin, mode of transmission, and contact tracing of SARS-CoV-2. The present review aims to highlight the recent advancements in the molecular epidemiological studies along with updating recent advancements in the molecular (nucleic acid based) diagnostics for COVID-19, the disease caused by SARS-CoV-2. Recent Findings Epidemiological studies with the integration of molecular genetics principles and tools are now mainly focused on the elucidation of molecular pathology of COVID-19. Molecular epidemiological studies have discovered the mutability of SARS-CoV-2 which is of utmost importance for the development of therapeutics and vaccines for COVID-19. The whole world is now participating in the race for development of better and rapid diagnostics and therapeutics for COVID-19. Several molecular diagnostic techniques have been developed for accurate and precise diagnosis of COVID-19. Summary Novel genomic techniques have helped in the understanding of the disease pathology, origin, and spread of COVID- 19.
  • Diabetic Foot and Gangrene

    Diabetic Foot and Gangrene

    11 Diabetic Foot and Gangrene Jude Rodrigues and Nivedita Mitta Department of Surgery, Goa Medical College, India 1. Introduction “Early intervention in order to prevent potential disaster in the management of Diabetic foot is not only a great responsibility, but also a great opportunity” Despite advances in our understanding and treatment of diabetes mellitus, diabetic foot disease still remains a terrifying problem. Diabetes is recognized as the most common cause of non-traumatic lower limb amputation in the western world, with individuals over 20 times more likely to undergo an amputation compared to the rest of the population. There is growing evidence that the vascular contribution to diabetic foot disease is greater than was previously realised. This is important because, unlike peripheral neuropathy, Peripheral Arterial Occlusive Disease (PAOD) due to atherosclerosis, is generally far more amenable to therapeutic intervention. PAOD, has been demonstrated to be a greater risk factor than neuropathy in both foot ulceration and lower limb amputation in patients with diabetes. Diabetes is associated with macrovascular and microvascular disease. The term peripheral vascular disease may be more appropriate when referring to lower limb tissue perfusion in diabetes, as this encompasses the influence of both microvascular dysfunction and PAOD. Richards-George P. in his paper about vasculopathy on Jamaican diabetic clinic attendees showed that Doppler measurements of ankle/brachial pressure index (A/BI) revealed that 23% of the diabetics had peripheral occlusive arterial disease (POAD) which was mostly asymptomatic. This underscores the need for regular Doppler A/BI testing in order to improve the recognition, and treatment of POAD.
  • Role and Limitations of Epidemiology in Establishing a Causal Association Eduardo L

    Role and Limitations of Epidemiology in Establishing a Causal Association Eduardo L

    Seminars in Cancer Biology 14 (2004) 413–426 Role and limitations of epidemiology in establishing a causal association Eduardo L. Franco a,∗, Pelayo Correa b, Regina M. Santella c, Xifeng Wu d, Steven N. Goodman e, Gloria M. Petersen f a Departments of Epidemiology and Oncology, McGill University, 546 Pine Avenue West, Montreal, QC, Canada H2W1S6 b Department of Pathology, Louisiana State University Health Sciences Center, New Orleans, LA, USA c Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA d Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA e Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA f Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA Abstract Cancer risk assessment is one of the most visible and controversial endeavors of epidemiology. Epidemiologic approaches are among the most influential of all disciplines that inform policy decisions to reduce cancer risk. The adoption of epidemiologic reasoning to define causal criteria beyond the realm of mechanistic concepts of cause-effect relationships in disease etiology has placed greater reliance on controlled observations of cancer risk as a function of putative exposures in populations. The advent of molecular epidemiology further expanded the field to allow more accurate exposure assessment, improved understanding of intermediate endpoints, and enhanced risk prediction by incorporating the knowledge on genetic susceptibility. We examine herein the role and limitations of epidemiology as a discipline concerned with the identification of carcinogens in the physical, chemical, and biological environment. We reviewed two examples of the application of epidemiologic approaches to aid in the discovery of the causative factors of two very important malignant diseases worldwide, stomach and cervical cancers.
  • Glossary of Terms Related to Patient and Medication Safety

    Glossary of Terms Related to Patient and Medication Safety

    Committee of Experts on Management of Safety and Quality in Health Care (SP-SQS) Expert Group on Safe Medication Practices Glossary of terms related to patient and medication safety Terms Definitions Comments A R P B and translations and references and synonyms accident accident : an unplanned, unexpected, and undesired event, usually with adverse “For many years safety officials and public health authorities have Xconsequences (Senders, 1994). discouraged use of the word "accident" when it refers to injuries or the French : accident events that produce them. An accident is often understood to be Spanish : accidente unpredictable -a chance occurrence or an "act of God"- and therefore German : Unfall unavoidable. However, most injuries and their precipitating events are Italiano : incidente predictable and preventable. That is why the BMJ has decided to ban the Slovene : nesreča word accident. (…) Purging a common term from our lexicon will not be easy. "Accident" remains entrenched in lay and medical discourse and will no doubt continue to appear in manuscripts submitted to the BMJ. We are asking our editors to be vigilant in detecting and rejecting inappropriate use of the "A" word, and we trust that our readers will keep us on our toes by alerting us to instances when "accidents" slip through.” (Davis & Pless, 2001) active error X X active error : an error associated with the performance of the ‘front-line’ operator of Synonym : sharp-end error French : erreur active a complex system and whose effects are felt almost immediately. (Reason, 1990, This definition has been slightly modified by the Institute of Medicine : “an p.173) error that occurs at the level of the frontline operator and whose effects are Spanish : error activo felt almost immediately.” (Kohn, 2000) German : aktiver Fehler Italiano : errore attivo Slovene : neposredna napaka see also : error active failure active failures : actions or processes during the provision of direct patient care that Since failure is a term not defined in the glossary, its use is not X recommended.
  • Molecular Epidemiology and Whole-Genome Analysis of Bovine Foamy Virus in Japan

    Molecular Epidemiology and Whole-Genome Analysis of Bovine Foamy Virus in Japan

    viruses Article Molecular Epidemiology and Whole-Genome Analysis of Bovine Foamy Virus in Japan Hirohisa Mekata 1,* , Tomohiro Okagawa 2, Satoru Konnai 2,3 and Takayuki Miyazawa 4 1 Center for Animal Disease Control, University of Miyazaki, Miyazaki 889-2192, Japan 2 Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan; [email protected] (T.O.); [email protected] (S.K.) 3 Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan 4 Laboratory of Virus-Host Coevolution, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan; [email protected] * Correspondence: [email protected]; Tel./Fax: +81-985-58-7881 Abstract: Bovine foamy virus (BFV) is a member of the foamy virus family in cattle. Information on the epidemiology, transmission routes, and whole-genome sequences of BFV is still limited. To understand the characteristics of BFV, this study included a molecular survey in Japan and the determination of the whole-genome sequences of 30 BFV isolates. A total of 30 (3.4%, 30/884) cattle were infected with BFV according to PCR analysis. Cattle less than 48 months old were scarcely infected with this virus, and older animals had a significantly higher rate of infection. To reveal the possibility of vertical transmission, we additionally surveyed 77 pairs of dams and 3-month-old calves in a farm already confirmed to have BFV. We confirmed that one of the calves born from a dam with BFV was infected.
  • Molecular Pathological Epidemiology Gives Clues to Paradoxical Findings

    Molecular Pathological Epidemiology Gives Clues to Paradoxical Findings

    Molecular Pathological Epidemiology Gives Clues to Paradoxical Findings The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Nishihara, Reiko, Tyler J. VanderWeele, Kenji Shibuya, Murray A. Mittleman, Molin Wang, Alison E. Field, Edward Giovannucci, Paul Lochhead, and Shuji Ogino. 2015. “Molecular Pathological Epidemiology Gives Clues to Paradoxical Findings.” European Journal of Epidemiology 30 (10): 1129–35. https://doi.org/10.1007/ s10654-015-0088-4. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:41392032 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#OAP HHS Public Access Author manuscript Author Manuscript Author ManuscriptEur J Epidemiol Author Manuscript. Author Author Manuscript manuscript; available in PMC 2016 October 07. Published in final edited form as: Eur J Epidemiol. 2015 October ; 30(10): 1129–1135. doi:10.1007/s10654-015-0088-4. Molecular Pathological Epidemiology Gives Clues to Paradoxical Findings Reiko Nishiharaa,b,c, Tyler J. VanderWeeled,e, Kenji Shibuyac, Murray A. Mittlemand,f, Molin Wangd,e,g, Alison E. Fieldd,g,h,i, Edward Giovannuccia,d,g, Paul Lochheadi,j, and Shuji Oginob,d,k aDepartment of Nutrition, Harvard T.H. Chan School of Public Health, 655 Huntington Ave., Boston, Massachusetts 02115 USA bDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave., Boston, Massachusetts 02215 USA cDepartment of Global Health Policy, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan dDepartment of Epidemiology, Harvard T.H.